Women's health needs are overlooked, resulting in a staggering average of nine years spent in ill health – 25% more than men endure. The report "Closing Women’s Health Gap: a $1 Trillion Opportunity to Improve Lives and Economies," sheds light on the benefits of narrowing this gap.
Developed by the World Economic Forum, McKinsey Health Institute, and the Global Alliance for Women’s Health, this groundbreaking report quantifies the severe socio-economic impacts and highlights the vast benefits of closing the women’s health gap. It's a call to action for a fundamental mindset shift and bold, cross-sector investments.
Endometriosis takes center stage, representing a significant area of unmet needs and promising major improvements.
This report is a wake-up call – no single business or organization can tackle these challenges alone. It's time for collaborative efforts to create meaningful change.
Read the full report here: https://initiatives.weforum.org/global-alliance-for-womens-health/initiative-1
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.
Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.